
Dr. Robert Fremeau
Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.
Computational biology, software development, and genetics expertise
Dr. Edoardo Marcora has a strong academic and industry background in experimental and computational biology, neuroscience, human genetics, functional genomics, software development, and drug discovery. Throughout his graduate training at the University of Colorado at Boulder and his post-doctoral training at the California Institute of Technology (Caltech), he has investigated the role of transcription factors in neurodegeneration using various experimental and computational approaches. While on sabbatical at the European Bioinformatics Institute, he co-developed BioMart, a computational tool for genomic data integration and mining. As a Principal Investigator in the Department of Neuroscience Discovery at Amgen, he led and supported cross-functional teams identifying and validating drug targets for Alzheimer’s disease using human genetics, systems biology, and experimental biology approaches. Throughout his career, Edoardo has pioneered the use of systems genetics and integrative genomics coupled with targeted genome editing and high-content screening for the identification and validation of novel genetic risk factors and drug targets for Alzheimer’s disease.

Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.

Co-founder and CSO
Neurobiologist with 5+ years of experience in cortical organoid disease models and applications of bioinformatics/machine learning in drug discovery.

Stem cell and brain organoid pioneer
Created the first human organoid models for neurodevelopmental disorders.

Experienced biotech C-suite officer
Current BOD, SAB member, and former CEO at ADRx, Inc.

Innovative medicinal chemist
30+ years of drug discovery and development experience.

Business development professional with deep commercial experience
19+ years building new markets and driving paradigm-shifting tools into biopharma, government, and academic organizations.
Talk to us about our precision neuroscience platform, our Parkinson’s disease program, or working with the BrainStorm team.